Sonnet Biotherapeutics Holdings Inc. is a forward-thinking biotechnology company located in Princeton, New Jersey, specializing in the development of advanced oncological therapies through its proprietary platform for single-acting and bispecific biologics. The firm is committed to addressing critical unmet medical needs in cancer care by leveraging cutting-edge biotechnological innovations to create targeted treatments. With a strong focus on next-generation biologics, Sonnet aims to reshape treatment paradigms and enhance patient outcomes, positioning itself as a key player in the evolving oncology landscape. Show more

Location: 100 OVERLOOK CENTER, PRINCETON, NJ, UNITED STATES, 08540, Princeton, NJ, 08540, USA | Website: https://www.sonnetbio.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

8.603M

52 Wk Range

$1.08 - $10.38

Previous Close

$3.10

Open

$3.16

Volume

10,456,154

Day Range

$1.26 - $3.23

Enterprise Value

8.35M

Cash

321.3K

Avg Qtr Burn

-1.759M

Insider Ownership

4.25%

Institutional Own.

9.95%

Qtr Updated

06/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
SON-080 Details Chemotherapy-Induced Peripheral Neuropathy & Diabetic Peripheral Neuropathy (DPN)	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SON-1010 + Atezolizumab Details Platinum-resistant ovarian cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SON-1210 w/ chemotherapeutic agents Details Advanced Solid Tumors & Pancreatic cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SON-1010 (IL12-FHAB) +/- Trabectedin Details Leiomyosarcoma (LMS) or liposarcoma (LPS)	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.